Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
In almost 1,000 twin pregnancies with known outcomes, cell-free DNA screening of maternal blood correctly classified trisomy 21 cases 94 percent of the time.
According to Natantis, researchers will be able to use the device to extract cell-free nucleic acids from whole blood in 45 minutes.
In Nature this week: Integrative Human Microbiome Project researchers investigate host-microbiome relationship in health and disease, and more.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.